Enbrel sales force consolidated under Amgen as approval nears for Pfizer RA drug
This article was originally published in Scrip
Executive Summary
Amgen and Pfizer have shifted some of the responsibilities under their co-promotion partnership for the blockbuster rheumatoid arthritis biologic Enbrel (etanercept) more than a year ahead of schedule and on the heels of a US FDA decision on Pfizer's competing drug due this summer.